###begin article-title 0
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Glutamic Acid Decarboxylase-Derived Epitopes with Specific Domains Expand CD4+CD25+ Regulatory T Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: GC GH JF YL. Performed the experiments: GC GH JF JW RW RX. Analyzed the data: GC GH JF BS JQ YL. Wrote the paper: GC JF YL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+CD25+ regulatory T cell (Treg)-based immunotherapy is considered a promising regimen for controlling the progression of autoimmune diabetes. In this study, we tested the hypothesis that the therapeutic effects of Tregs in response to the antigenic epitope stimulation depend on the structural properties of the epitopes used.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 276 284 276 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 326 327 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 452 453 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 457 458 457 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 762 764 762 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 957 959 957 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 1097 1099 1097 1099 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 1131 1133 1131 1133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 1383 1384 1383 1384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1388 1389 1388 1389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 1438 1442 <span type="species:ncbi:10090">mice</span>
Splenic lymphocytes from nonobese diabetic (NOD) mice were stimulated with different glutamic acid decarboxylase (GAD)-derived epitopes for 7-10 days and the frequency and function of Tregs was analyzed. We found that, although all expanded Tregs showed suppressive functions in vitro, only p524 (GAD524-538)-expanded CD4+CD25+ T cells inhibited diabetes development in the co-transfer models, while p509 (GAD509-528)- or p530 (GAD530-543)-expanded CD4+CD25+ T cells had no such effects. Using computer-guided molecular modeling and docking methods, the differences in structural characteristics of these epitopes and the interaction mode (including binding energy and identified domains in the epitopes) between the above-mentioned epitopes and MHC class II I-Ag7 were analyzed. The theoretical results showed that the epitope p524, which induced protective Tregs, possessed negative surface-electrostatic potential and bound two chains of MHC class II I-Ag7, while the epitopes p509 and p530 which had no such ability exhibited positive surface-electrostatic potential and bound one chain of I-Ag7. Furthermore, p524 bound to I-Ag7 more stably than p509 and p530. Of importance, we hypothesized and subsequently confirmed experimentally that the epitope (GAD570-585, p570), which displayed similar characteristics to p524, was a protective epitope by showing that p570-expanded CD4+CD25+ T cells suppressed the onset of diabetes in NOD mice.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
These data suggest that molecular modeling-based structural analysis of epitopes may be an instrumental tool for prediction of protective epitopes to expand functional Tregs.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 225 228 222 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Kaufman1">[1]</xref>
###xml 229 232 226 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Ellis1">[3]</xref>
###xml 441 444 438 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tisch1">[4]</xref>
###xml 446 449 443 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Atkinson1">[5]</xref>
###xml 642 645 636 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Yoon1">[6]</xref>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
###xml 407 413 <span type="species:ncbi:9606">humans</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
Glutamic acid decarboxylase (GAD65), consisting of 585 amino acids, has been shown to be the first of several beta cell antigens to be recognized by T cells from nonobese diabetic (NOD) mice and patients with type 1 diabetes [1]-[3]. Its importance in the pathogenesis of autoimmune diabetes is indicated by the following evidence: 1. T cell responses against GAD65 can be detected in young NOD mice and in humans at risk of type 1 diabetes [4], [5]; 2. beta cell-specific suppression of GAD65 expression in antisense GAD65 transgenic NOD mice leads to complete prevention of type 1 diabetes and blocks the generation of diabetogenic T cells [6]. These findings suggest that modulation of GAD65 autoimmunity can influence the development of type 1 diabetes in NOD mice.
###end p 9
###begin p 10
###xml 194 197 194 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-DiLorenzo1">[7]</xref>
###xml 335 338 335 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tian1">[8]</xref>
###xml 365 368 365 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Quinn1">[9]</xref>
###xml 1196 1200 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tisch2">[10]</xref>
###xml 1202 1206 1199 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Chen1">[11]</xref>
###xml 1309 1313 1306 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Sakaguchi1">[12]</xref>
###xml 1446 1450 1440 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tarbell1">[13]</xref>
###xml 1572 1580 1566 1574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 1085 1089 <span type="species:ncbi:10090">mice</span>
It is known that GAD65 contains dozens of epitopes which are specifically recognized by T cells as peptide epitope-MHC complexes on the surface of target cells thereby directing T cell function [7]. Indeed, pretreatment of prediabetic NOD mice with GAD65 or some of its peptide epitopes efficiently delays the onset of type 1 diabetes [8]. Strikingly, Quinn et al. [9] found the presence of two kinds of epitopes (named as effector and regulatory or protective epitopes) in GAD65 which were completely different in their mediation of T cell function and the pathogenesis of diabetes. Although many factors such as the mature state of antigen processing cells (APC) contribute to determining whether an epitope is an effector or regulatory epitope, the physical-chemical properties of epitopes may have important effects on their function. Differential structural properties of epitopes probably lead to divergent conformation of MHC class II molecules bound to the corresponding epitopes and ultimately to differential T cell functional activation. Peptide epitope immunization in NOD mice is associated with the induction of Tregs that secrete IL-10 and/or transforming growth factor (TGF)-beta [10], [11]. These cells have been shown to be pivotal for immune homeostasis and protection against autoimmunity [12]. Recently, it is reported that Tregs can be expanded by dendritic cells bearing an autoantigenic peptide from pancreatic beta cells [13]. Thus, we postulate that there is a difference between effector and regulatory epitopes in their ability to expand Tregs in vitro.
###end p 10
###begin p 11
###xml 79 86 79 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Han1">[14]</xref>
###xml 251 258 251 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 412 415 412 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Kaufman1">[1]</xref>
###xml 417 420 417 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Quinn1">[9]</xref>
###xml 509 510 509 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 514 515 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 524 531 524 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 557 564 557 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 606 607 606 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 611 612 611 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 814 821 814 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
Previous research in our lab has demonstrated that a single immunization of GAD500-585 (a peptide of GAD65) in young NOD mice remarkably reduced pancreatic insulitis and efficiently prevented the development of overt type 1 diabetes [14]. In fact, GAD500-585 is composed of multiple epitopes such as 509-528, 524-538 and 530-543, which are important autoantigenic peptides for the development of type 1 diabetes [1], [9]. In this study, the potential capacity of the above three peptide epitopes to expand CD4+CD25+ T cells ex vivo was investigated and the in vivo suppressive effects of these expanded CD4+CD25+ T cells were then examined. Furthermore, a potential relationship between the structure and function of these epitopes was analyzed by molecular modeling/docking methods and a novel epitope p570 in GAD500-585 which induced protective Tregs was presented.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 13
###begin p 14
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
NOD, and NOD.scid female mice were obtained from the Jackson Laboratory and bred in our facilities under specific pathogen-free conditions. Care, use and treatment of mice in this study was in strict agreement with guidelines in the care and use of laboratory animal manual set out by the Institute of Basic Medical Sciences. Diabetes monitoring was performed on a weekly measurement basis. The female NOD mice develop overt diabetes at the age of 12 wks and the incidence reaches 80% by 25 wks of age.
###end p 14
###begin title 15
Epitope analysis and synthesis
###end title 15
###begin p 16
###xml 30 37 30 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 111 163 111 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Zhao1">[http://www.biosun.org.cn/biosun/intro.htm, ref. 15]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Hopp1">[16]</xref>
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Garnier1">[17]</xref>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Welling1">[18]</xref>
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Janin1">[19]</xref>
###xml 422 429 422 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 682 689 682 689 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
The continuous epitopes of GAD500-585 were determined based on its primary structure using the BIOSUN software [http://www.biosun.org.cn/biosun/intro.htm, ref. 15] bearing in mind its hydrophilic-hydrophobic properties [16], secondary structure [17], antigenicity [18] and accessibility of the residues [19]. In order to understand the relationship between sequence and structure in greater depth, the 3-D structure of GAD500-585 was constructed using the homology modeling method (InsightII software (2005), Accelrys, San Diego, CA) based on the crystal structure of GAD65. To optimize the packing interactions through protein side-chain repacking, the 3-D modeled structure of GAD500-585 was minimized with molecular mechanics method under Consistent Valence Force Field (CVFF) and Gromos96 force field, respectively. Atomic charges were taken from the corresponding force field package. Cross-terms were not used and energy convergence was considered to have been obtained when the maximum derivative reached 4.2 J/A by the conjugate gradients method.
###end p 16
###begin p 17
###xml 91 98 91 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 406 413 406 413 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 819 821 819 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
The surface electrostatic potential was calculated based on the stable 3-D structure of GAD500-585, using the DELPHI program (InsightII software (2005), Accelrys, San Diego, CA). The charges of the ionized groups were assigned assuming standard amino acid protonation state at pH 7. Hisidines were considered in the neutral form. The CVFF partial atomic charges were used and the dielectric constant of GAD500-585 and solvent (i.e. water) were set to 2 and 80, respectively. An ion exclusion layer was added to the solutions and extended 10 A beyond the molecular surfaces. The non-linear Poisson-Boltzmann equation was solved in the finite difference approximation, and the numerical calculations of the potential were iterated to convergence, which was defined as the point at which the potential changes less than 10-4 kT/emol between successive iterations.
###end p 17
###begin p 18
GAD peptides p509, p524, p530 and p570 were synthesized at Genemed Synthesis, and were brought to >90% purity using reverse phase HPLC. Peptide purity was determined by capillary electrophoresis, and the amino acid composition of the peptides was verified by mass spectrometry. Ovalbumin (OVA) was purchased from Sigma-Aldrich (USA).
###end p 18
###begin title 19
Molecular docking
###end title 19
###begin p 20
###xml 74 83 74 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ab initio</italic>
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Fanelli1">[20]</xref>
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Ortiz1">[21]</xref>
3-D structures of the above-mentioned peptides were constructed using the ab initio modeling method [20], [21]. Firstly, secondary structures of the peptides were predicted and dihedral angles were determined. 3-D original structures of the peptides were then modeled. Finally, the stable structures of the peptides were obtained under CVFF using molecular mechanics optimization.
###end p 20
###begin p 21
###xml 142 144 142 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 119 125 <span type="species:ncbi:10090">murine</span>
Using the 3-D crystal structure of the MHC II molecule and the modeling structure of the GAD65 peptide in complex with murine MHC class II I-Ag7 (PDB code: 1es0) as templates, bearing in mind Van der Waals and intermolecular hydrogen bonding interactions, the 3-D structures of the peptides in complex with the MHC class II molecule were constructed and optimized with the molecular docking method.
###end p 21
###begin p 22
In order to minimize steric clashes and ensure correct interaction non-bond distances, angles and hydrogen bonds after molecular docking, the interaction domains between the peptides and MHC class II molecule were subjected to 5000 steps of energy minimization, while the remainder was held fixed in position. To avoid the conformation of the interaction domains trapped in a local potential energy minimum, residues at the base of the interaction domains were held fixed while the remainder of the interaction domains was subjected to simulated heating and molecular dynamics at elevated temperatures followed by slow cooling to a low energy conformation. The interaction domain residues were initially assigned a temperature of 300K and slowly heated to 500K in increments of 25K, with 50 dynamics steps at each temperature using a time step of 1 fs. The structure was similarly heated to 1000, 2000, 3000 and 4000K. At each temperature the interaction domains were subjected to a 100 ps dynamics run followed by slowing to 300K, and two series of minimizations, first for 500 steps, then 3000 steps.
###end p 22
###begin title 23
Flow cytometry
###end title 23
###begin p 24
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 645 646 645 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
Antibodies used for flow cytometry were as follows: PE-labeled mAbs to CD4 (GK1.5), LAG-3 (C9B7W), CTLA-4 (UC10-4F10-11) and ICOS (7E.17G9) were purchased from BD Pharmingen, and FITC-labeled anti-CD4 (GK1.5) and PE-Cy5-labeled anti-CD25 (PC61) mAbs, PE-conjugated mAbs against GITR (DTA-1), and Foxp3 (FJK-16s) were purchased from eBioscience. Cells were stained in PBS containing 2% heat-inactivated FCS and 0.2% sodium azide, and fixed using PBS containing 1% paraformaldehyde. For intracellular staining, cells were first stained with Abs for 30 min and then fixed for 20 min with 1 ml fixation buffer (Fix & Perm cell permeabilization kit; eBioscience). After washing, the fixed cells were incubated with Abs for 30 min. Data collection and analysis were performed on a FACS Calibur flow cytometer using CellQuest software (Becton Dickinson).
###end p 24
###begin title 25
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro expansion of epitope-specific T cells
###end title 25
###begin p 26
###xml 356 357 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 180 185 <span type="species:ncbi:9796">horse</span>
Splenic lymphocytes were isolated from 4-8 wk old female NOD mice and cultured with different peptide epitopes or OVA control (50 ng/ml) in RPMI-1640 medium, which consisted of 1% horse serum (Hyclone), nonessential amino acids, 0.5 mM sodium pyruvate, 5 mM Hepes, 1 microM beta-mercaptoethanol. The cultures were monitored daily and maintained at 1-1.5x106/ml by diluting with complete medium for 7-10 days.
###end p 26
###begin title 27
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 38 46 38 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Purification of CD4+CD25+ T cells and in vitro suppression assays
###end title 27
###begin p 28
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 97 101 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Song1">[22]</xref>
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 184 185 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 432 433 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 437 438 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 446 447 446 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 451 452 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
Purification of CD4+CD25+ T cells by MACS (Miltenyi Biotec, Germany) was as described previously [22]. In brief, CD4+ T cells were isolated by depletion of magnetically labeled non-CD4+ T cells. CD4+ T cells labeled with PE-conjugated anti-CD25 were then magnetically labeled with anti-PE microbeads. The magnetically labeled cells were passed through a column placed in the magnetic field of a MACS separator and separated into CD4+CD25+ and CD4+CD25- T cells (purity>96%).
###end p 28
###begin p 29
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 241 242 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 270 271 266 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 275 276 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 462 463 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
For suppression assays, graded numbers of expanded or freshly purified CD4+CD25+ T cells were added to 50,000 CD4+ T cells stimulated with 50,000 irradiated splenic APCs (2,000 rads) and 1 microg/ml anti-CD3 in U-bottomed 96-well plates. CD4+ T cell cultures without CD4+CD25+ T cells were stimulated in the same manner as positive controls. The cultures were maintained at 37degreesC for a total of 72 h and cell proliferation was measured by incorporation of [3H]thymidine (1 microCi/well) during the final 16 h of culture.
###end p 29
###begin title 30
Adoptive transfer
###end title 30
###begin p 31
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 364 365 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 369 370 369 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 386 387 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 473 477 <span type="species:ncbi:10090">mice</span>
###xml 684 689 <span type="species:ncbi:10090">mouse</span>
###xml 760 765 <span type="species:ncbi:10090">mouse</span>
###xml 868 872 <span type="species:ncbi:10090">mice</span>
Epitope-expanded CD4+CD25+ T cells were purified as described above and injected intravenously (at different cell numbers, as indicated) into 4-8 wk old NOD.scid mice along with diabetogenic splenocytes isolated from acutely diabetic NOD mice. Recipients only receiving diabetogenic splenocytes were regarded as positive controls. In some experiments, expanded CD4+CD25+ T cells (1-3x106) were transfused into 4-6 wk old NOD mice. In combination of adoptive transfer, some mice received intraperitoneally antibodies to IL-10/TGF-beta or isotype IgG (all from R&D systems), respectively. The regimens of antibodies to IL-10 and TGF-beta administration were following: a dose of 0.5 mg/mouse on days -1, 0, 2, 5, then every 5 days for anti-IL-10; a dose of 1 mg/mouse on days 0, 3, 5, 8, then every 5 days for anti-TGF-beta. Nonfasting blood glucose levels in recipient mice were monitored using a MediSense glucometer (Abbott Laboratories) and blood glucose >/=300 mg/dl was considered diabetic.
###end p 31
###begin title 32
ELISA of cytokine production
###end title 32
###begin p 33
After splenocytes were incubated as described above, supernatants were harvested and IL-2, IL-10 and TGF-beta production was assayed by sandwich ELISA. The ELISA kits used in this study were purchased from BD Pharmingen.
###end p 33
###begin title 34
Statistical analysis
###end title 34
###begin p 35
###xml 96 97 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The Kaplan-Meier method was used to compare diabetes-free survival and incidence. The Student's t-test was used to compare mean values. Values of P<0.05 were considered significant.
###end p 35
###begin title 36
Results
###end title 36
###begin p 37
###xml 3 10 3 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
GAD500-585-derived peptide epitope stimulation expands CD4+CD25+Foxp3+ T cells from NOD mice
###end p 37
###begin p 38
###xml 219 223 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tarbell1">[13]</xref>
###xml 296 303 293 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500-585</sub>
###xml 559 560 556 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 564 565 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 583 587 580 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Hori1">[23]</xref>
###xml 588 592 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Zheng1">[25]</xref>
###xml 597 598 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 602 603 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 608 609 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 789 805 786 802 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1a and 1b</bold>
###xml 789 805 786 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g001"><bold>Figure 1a and 1b</bold></xref>
###xml 907 911 904 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Salomon1">[26]</xref>
###xml 964 968 961 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Shimizu1">[27]</xref>
###xml 1000 1004 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Herman1">[28]</xref>
###xml 1044 1048 1041 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Huang1">[29]</xref>
###xml 1095 1104 1092 1101 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1c</bold>
###xml 1095 1104 1092 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g001"><bold>Figure 1c</bold></xref>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
Steinman and colleagues reported that beta-cell autoantigenic peptide-bearing dendritic cells (DCs) expanded functionally competent Tregs which subsequently suppressed diabetes development in an antigen-specific manner [13]. Here, in order to determine whether known autoantigenic epitopes of GAD500-585, such as p509, p524 and p530, could also expand suppressive Tregs, splenic lymphocytes from autoimmune diabetes-prone NOD mice were exposed to stimulation from different peptide epitopes for 7-10 days. Since Foxp3 is known to be a master regulator for CD4+CD25+ Treg development [23]-[25], CD4+CD25+Foxp3+ T cells were examined. We found that the percentage and number of these cells increased 2-10 fold in response to stimulation with the above peptide epitopes compared to controls (Figure 1a and 1b). In addition, Treg-associated molecules, such as cytotoxic T lymphocyte-associated antigen (CTLA)-4 [26], glucocorticoid-induced TNFR-related protein (GITR) [27], inducible costimulator (ICOS) [28] and lymphocyte activation gene (LAG)-3 [29], were also up-regulated compared to controls (Figure 1c).
###end p 38
###begin title 39
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
In vitro expansion of CD4+CD25+ Foxp3+ T cells by peptide epitope stimulation.
###end title 39
###begin p 40
###xml 229 230 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 235 236 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 247 248 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 293 294 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 304 305 304 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 568 569 568 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 573 574 573 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 579 580 579 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 716 717 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Splenic lymphocytes were isolated from one NOD mice (total number of mice was 6) and cultured with different peptide epitopes (50 ng/ml) for 7-10 d. Cells were collected and analysed by flow cytometry. (a) The percentages of CD25+Foxp3+ within CD4+cells were presented. (b) Total number of CD4+CD25+Foxp3+ T cells in each group after expansion. Data collected from three independent experiments are shown. (c) Expression of Treg-related phenotypes (CTLA-4, GITR, ICOS, LAG-3) in CD4 T cells from each group. As controls, OVA (50 ng/ml) stimulation could not expand CD4+CD25+Foxp3+ T cells and up-regulate the expression of Treg-related molecules (data not shown). Data are shown as means+/-SD, n = 5-6 per group. *, P<0.05 compared with controls.
###end p 40
###begin p 41
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 175 176 175 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 325 332 325 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Results</xref>
###xml 361 362 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 574 582 574 582 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 574 582 574 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g002"><bold>Figure 2</bold></xref>
###xml 624 631 624 631 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 652 653 652 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 657 658 657 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 683 691 683 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
To further determine whether the peptide epitope-expanded CD4+CD25+ T cells were functionally suppressive, these expanded cells were examined for their ability to suppress CD4+ T effector cells (Teffs) from diabetic NOD mice. Tregs and Teffs were co-cultured in the presence of anti-CD3 and irradiated APC at a titred ratio. Results showed that the expanded CD4+CD25+ T cells efficiently suppressed proliferation of effector cells. This suppressive effect was more potent than for freshly isolated Tregs, as suppression was routinely observed at a Treg/Teff ratio of <1:32 (Figure 2). These results show that suppressive GAD500-585 epitope-expanded CD4+CD25+ T cells can be obtained in vitro by addition of peptide epitopes to pulse splenic APC.
###end p 41
###begin title 42
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
In vitro suppression by expanded CD4+CD25+ T cells.
###end title 42
###begin p 43
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 254 255 254 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 275 282 275 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Results</xref>
CD4+CD25+ T cells (R) with or without peptide epitope stimulation were compared for their ability to suppress the proliferation of CD4+ effector T cells (E) stimulated with anti-CD3 and irradiated APC at graded ratios. The proliferation was measured by [3H]thymidine uptake. Results are shown as means+/-SD. The data were collected from six to eight separate experiments.
###end p 43
###begin p 44
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 253 262 253 262 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3a</bold>
###xml 253 262 253 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g003"><bold>Figure 3a</bold></xref>
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Yamanouchi1">[30]</xref>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Bayer1">[31]</xref>
###xml 384 385 384 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 389 390 389 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 510 526 507 523 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3b and 3c</bold>
###xml 510 526 507 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g003"><bold>Figure 3b and 3c</bold></xref>
###xml 562 563 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 567 568 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Next, to determine the mechanisms underlying inhibitory effects of the expanded CD4+CD25+ T cells, we examined their cytokine profiles in response to differential epitope stimulation. The CD4+CD25+ T cells from each group secreted high amounts of IL-2 (Figure 3a), in line with the hypothesis that IL-2 is a key cytokine for expansion and survival of Tregs [30], [31]. Strikingly, CD4+CD25+ T cells produced more IL-10 and TGF-beta in response to p524 stimulation than in response to p509 or p530 stimulation (Figure 3b and 3c), indicating that p524-expanded CD4+CD25+ T cells may be more competent. We also examined IL-4 and IFN-gamma production, but no significant differences were found between the p509, p524 and p530 stimulation groups (data not shown).
###end p 44
###begin title 45
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cytokine production of expanded CD4+CD25+ T cells after peptide epitope stimulation.
###end title 45
###begin p 46
###xml 111 112 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 116 117 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 160 167 157 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Results</xref>
###xml 259 260 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
After 7-10d incubation with different peptide epitopes, the IL-2, IL-10 and TGF-beta production of expanded CD4+CD25+ T cells was determined by sandwich ELISA. Results are shown as means+/-SD. The data were collected from four to six separate experiments. *, P<0.05 compared with controls.
###end p 46
###begin p 47
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 18 35 18 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD4<sup>+</sup>CD25<sup>+</sup> T cells</bold>
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
In vitro-expanded CD4+CD25+ T cells suppress adoptive transfer of diabetes in vivo
###end p 47
###begin p 48
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 92 93 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 255 256 255 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 260 261 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 275 276 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 368 369 368 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 373 374 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 471 472 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 492 500 492 500 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 492 500 492 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g004"><bold>Figure 4</bold></xref>
###xml 636 637 630 631 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 641 642 635 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 834 835 825 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 839 840 830 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 885 894 876 885 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4b</bold>
###xml 885 894 876 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g004"><bold>Figure 4b</bold></xref>
###xml 1238 1239 1223 1224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1243 1244 1228 1229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1355 1359 1340 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tang1">[32]</xref>
###xml 1410 1411 1395 1396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1415 1416 1400 1401 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1430 1431 1415 1416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 182 187 <span type="species:ncbi:10090">mouse</span>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
Using a co-transfer model, we subsequently examined the ability of epitope-expanded CD4+CD25+ T cells to suppress diabetes when co-transferred with diabetogenic T cells (1x107 cells/mouse) into NOD.scid mice. Interestingly, we found that p524-expanded CD4+CD25+ T cells (3x106) effectively blocked diabetes transfer, whereas the other two types of epitope-expanded CD4+CD25+ T cells did not show such protective effects, even when much higher numbers of expanded CD4+CD25+ T cells were used (Figure 4). Furthermore, neutralizing antibodies to IL-10/TGF-beta were administrated to evaluate the role of IL-10/TGF-beta in p524-expanded CD4+CD25+ T cell-mediated prevention from diabetes transfer. The results showed that blockade of IL-10/TGF-beta bioactivities in vivo dramatically abrogated the suppressive effects of p524-expanded CD4+CD25+ T cells on adoptively transfer of diabetes (Figure 4b). Intriguingly, the neutralization of one of these two cytokines (IL-10 or TGF-beta) just had minor effects on Treg-mediated blockade of diabetes development (data not shown), indicating a complementary role of IL-10 or TGF-beta in mediating Treg protective effects when one cytokine was removed. We also examined the ability of polyclonal CD4+CD25+ T cells expanded by anti-CD3 plus IL-2 for inhibition of diabetes transfer. Consistent with a previous report [32], our results showed that high numbers of these CD4+CD25+ T cells (6x106) were insufficient to prevent diabetes (data not shown).
###end p 48
###begin title 49
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
P524-expanded CD4+CD25+ T cells prevented transfer of diabetes.
###end title 49
###begin p 50
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 250 251 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 255 256 255 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 365 386 362 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 530 531 527 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 549 550 546 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 554 555 551 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 675 676 672 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 694 695 691 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 699 700 696 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
Diabetic splenocytes (1x107) were co-transferred with or without CD4+CD25+ T cells expanded by p509 (a), p524 (b), or p530 (c), to 4-8 wk old NOD.scid mice at the numbers indicated. In some cases, NOD.scid recipients receiving 6x106 p524-expanded CD4+CD25+ T cells were injected with neutralizing antibodies to IL-10/TGF-beta according to the regimens described in Materials and Methods. Blood glucose was monitored for up to 8 wks. Differences in blood glucose levels between diabetic spleens alone and diabetic spleens plus 3x106 p524-expanded CD4+CD25+ T cells were significant (P = 0.003), as were differences between diabetic spleens alone and diabetic spleens plus 6x106 p524-expanded CD4+CD25+ T cells (P = 0.002). Cumulative data from three experiments are shown. The number of mice in each group is indicated in parentheses.
###end p 50
###begin title 51
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
In vitro-expanded CD4+CD25+ T cells delay or suppress the onset of diabetes in prediabetic NOD mice
###end title 51
###begin p 52
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Barthlott1">[33]</xref>
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Stockinger1">[34]</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Pop1">[35]</xref>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Chen2">[37]</xref>
###xml 523 530 520 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 587 591 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Masteller1">[38]</xref>
###xml 593 597 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tarbell2">[39]</xref>
###xml 650 651 647 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 655 656 652 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 660 661 657 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 737 738 734 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 756 757 753 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 761 762 758 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 873 882 870 879 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5a</bold>
###xml 873 882 870 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g005"><bold>Figure 5a</bold></xref>
###xml 972 973 969 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 977 978 974 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1046 1062 1043 1059 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5a and 5b</bold>
###xml 1046 1062 1043 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g005"><bold>Figure 5a and 5b</bold></xref>
###xml 1177 1178 1171 1172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1182 1183 1176 1177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1362 1371 1353 1362 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5b</bold>
###xml 1362 1371 1353 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g005"><bold>Figure 5b</bold></xref>
###xml 1440 1441 1431 1432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1445 1446 1436 1437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 364 369 <span type="species:ncbi:10090">mouse</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 555 559 <span type="species:ncbi:10090">mice</span>
###xml 620 624 <span type="species:ncbi:10090">mice</span>
###xml 775 780 <span type="species:ncbi:10090">mouse</span>
Since the immunoregulatory activity of Tregs based on adoptive transfer models that take advantage of lymphopenic settings to enhance Treg proliferation can be explained by active regulation or a side effect of competition for "space" [33], [34], we further investigated the diabetes-suppressive function of Tregs in a nonlymphopenic autoimmune diabetes-prone NOD mouse model. Previous studies have shown that NOD mice are deficient in Treg number and function [35]-[37] and that intravenous transfer of beta cell-specific ex vivo expanded Tregs into NOD mice actively prevents diabetes [38], [39]. Thus, 4-6 wk old NOD mice were injected with 1-3x106 CD4+CD25+ T cells and subsequently monitored for diabetes. Transfer of as few as 1x106 p524-expanded CD4+CD25+ T cells per mouse markedly prevented/delayed the development of diabetes for as long as 25 wk after transfer (Figure 5a), whereas transfer of similar or even 3-fold greater numbers of p509 or p530-expanded CD4+CD25+ T cells only had a slight preventive effect on diabetes incidence (Figure 5a and 5b). In this setting, we also examined whether IL-10/TGF-beta cytokines played an essential role in p524-expanded CD4+CD25+ T cell-mediated delayed development of diabetes. The findings showed that neutralization of IL-10/TGF-beta in vivo significantly abolished the protective effects of these cells (Figure 5b), indicating that the immunoregulatory function of p524-expanded CD4+CD25+ T cells was partially attributed to high amounts of IL-10/TGF-beta produced by these cells. Taken together, these results suggested that Treg-mediated inhibition of diabetes development is epitope-specific.
###end p 52
###begin title 53
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
P524-expanded CD4+CD25+ T cells prevented/delayed the onset of diabetes in autoimmune diabetes-prone NOD mice.
###end title 53
###begin p 54
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 222 223 222 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 356 377 353 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 574 575 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 593 594 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 598 599 595 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 703 704 700 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 722 723 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 727 728 724 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
###xml 552 556 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 765 769 <span type="species:ncbi:10090">mice</span>
4-6 wk old NOD mice were transfused with CD4+CD25+ T cells (either 1x106 (a) or 3x106 (b) per mouse) expanded by p509, p524 or p530. Untreated littermates were used as controls. In some cases, NOD recipients receiving 3x106 p524-expanded CD4+CD25+ T cells were injected with neutralizing antibodies to IL-10/TGF-beta according to the regimens described in Materials and Methods. Development of diabetes was monitored for over 25 wks and the cumulative incidence of diabetes was shown from two experiments. The difference between untreated controls and mice treated with 1x106 p524-expanded CD4+CD25+ T cells was significant (P = 0.0036), as was that between untreated controls and mice treated with 3x106 p524-expanded CD4+CD25+ T cells (P = 0.0015). The number of mice in each group is indicated in parentheses.
###end p 54
###begin title 55
###xml 3 10 3 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
GAD500-585 epitope structure-function study
###end title 55
###begin p 56
###xml 308 315 308 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 374 382 374 382 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6</bold>
###xml 374 382 374 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g006"><bold>Figure 6</bold></xref>
###xml 565 572 565 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 1050 1054 1050 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Dai1">[40]</xref>
To determine whether this distinction in the Treg-expanding function of these epitopes was related to differences in their structural properties, physical and chemical features of p509, p524 and p530 were studied by surface property analysis and molecular modeling methods. The continuous epitopes of the GAD500-585 sequence were analyzed using BIOSUN software. As shown in Figure 6, peaks of the analyzed curve denoted the center of the continuous epitopes and peptides 509-528, 532-545, 530-543, 550-556, 562-574, and 570-584 appear to be the main epitopes of GAD500-585. In the above experiments, the epitopes p509 and p530 could be identified clearly, however p524 (GAD524-538) appeared to include two potential epitopes (i.e. the C-terminal of p509 and the N-terminal of p532). The predicted epitopes p509 and p530 were composed of one core epitope, while the epitope p524 was made up of two core epitopes. Our results are in line with a recent report that p524 and p530 share one core and that flanking residues are critical for their function [40]. Taken together, these results show a potential difference between p524, and p509 as well as p530.
###end p 56
###begin title 57
###xml 15 22 15 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
Epitopes in GAD500-585 were predicted using BIOSUN software bearing in mind sequence properties, the hydrophobic-hydrophilic map, secondary structure, antigenicity and accessibility.
###end title 57
###begin p 58
The X-coordinate denoted the sequence location in GAD500-585, of which the first value was the NO. 500 residue in GAD65 and the rest was deduced by analogy. The Y-coordinate denoted the statistical value from the sequence properties (including the hydrophobic-hydrophilic map, secondary structure, antigenicity and accessibility). The curve peak indicated the most possible key residue to form epitope. The region up the red line denoted the possible epitopes, and the region down the blue line denoted the impossible epitopes. The region between the blue and red lines indicated uncertain/potential epitopes. The peptides used in our study are marked as p509, p524, p530 and p570. The beginning and end points of the peptides are marked as vertical lines.
###end p 58
###begin p 59
###xml 103 110 103 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 258 265 258 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 296 305 296 305 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7a</bold>
###xml 296 305 296 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g007"><bold>Figure 7a</bold></xref>
###xml 330 337 330 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 466 473 466 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 527 534 527 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 687 694 687 694 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
To understand more deeply the structure-function relationship of the epitopes, the 3-D structure of GAD500-585 was modeled and optimized based on the crystal structure of GAD from the PDB database (PDB code: 2okk) and the predicted secondary structure of GAD500-585 (data not shown), as shown in Figure 7a. It can be seen that GAD500-585 is composed of three alpha helices and three beta sheets. Due to the presence of five proline residues, the 3-D structure of GAD500-585 is compact. Our computer-modeled 3-D structure of GAD500-585 was very similar to that in the original protein structure of GAD, and the RMSD (Root Mean Square Distance) value of main chain carbon atoms between GAD500-585 and GAD was 0.0464 nm.
###end p 59
###begin title 60
###xml 43 50 43 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
3-D structure and surface properties of GAD500-585.
###end title 60
###begin p 61
###xml 33 40 33 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 460 467 460 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
(a) 3-D modeling structure of GAD500-585, derived from the crystal structure of GAD65 using a computer modeling homology method and optimized using molecular mechanism and molecular dynamics methods under a CVFF forcefield, was shown as ribbon map and the secondary structure (composed of beta sheets and turns) was analyzed. (b) Surface electrostatic potential of the peptides p509, p524, p530, p570. The surface electrostatic potential of the residues in GAD500-585 was calculated using the DELPHI program, and the total surface electrostatic potential distribution of the peptides was summed. The positive value in Y-coordinate denoted the peptides possessed the positive surface electrostatic potential, and vice versa.
###end p 61
###begin p 62
###xml 59 66 59 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 123 130 123 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 201 210 201 210 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7b</bold>
###xml 201 210 201 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g007"><bold>Figure 7b</bold></xref>
###xml 212 219 212 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Results</xref>
Furthermore, according to the modeling 3-D structure of GAD500-585, the surface electrostatic potential distribution of GAD500-585 was analyzed using DELPHI program. The calculated values are shown in Figure 7b. Results showed that fragments p509 and p530 possessed positive surface electrostatic potential, while fragments p524 and p570 possessed negative surface electrostatic potential. The surface electrostatic potential difference of the peptides might be related to their bio-function. The peptides p509 and p530 might possess the similar function while p524 and p570 had the similar abilities.
###end p 62
###begin p 63
In summary, together with the experimental results, the conclusion is made that differences in the functions of p524, p509 and p530 in expanding competent Tregs may be due to differences in their structural properties.
###end p 63
###begin title 64
The structural mode of interaction with MHC II varies with peptide epitope
###end title 64
###begin p 65
###xml 123 132 123 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ab initio</italic>
###xml 217 219 217 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 319 321 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 399 407 399 407 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8</bold>
###xml 399 407 399 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g008"><bold>Figure 8</bold></xref>
###xml 506 510 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tarbell3">[41]</xref>
###xml 552 559 552 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Results</xref>
###xml 636 638 636 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 704 706 704 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 777 779 777 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
The 3-D structures of the peptide epitopes p509, p524, p530 and p570 were modeled using secondary structure prediction and ab initio modeling methods, and 3-D structures of the interaction of peptide epitopes with I-Ag7 were constructed by molecular docking methods, according to the 3-D crystal structure of MHC II I-Ag7 in complex with p207 (PDB code: 1es0). Optimized 3-D structures are shown in Figure 8. The peptide p286 from GAD65 (286-300), whose transgenic expression delayed the onset of diabetes [41], was also analyzed by way of comparison. Results showed that p524 and p570 possessed a similar binding pattern to that of I-Ag7 with p286. The two peptides interacted with the middle of the I-Ag7 chain A and B. In contrast, peptides p509 and p530 interacted with I-Ag7 chain B, but not with chain A.
###end p 65
###begin title 66
###xml 107 109 107 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
3-D optimized structures of the peptides (p286, p509, p524, p530 and p570) in complex with MHC class II I-Ag7 using molecular docking and molecular dynamics methods.
###end title 66
###begin p 67
###xml 108 110 108 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 176 178 176 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
The red ribbon denoted the peptides and the blue and green ribbons denoted the dimer of the MHC class II I-Ag7. The peptides p509 and p530 bound monomer of the MHC class II I-Ag7, while the peptides p524 and p570 bound the core domain of the dimmer similar to the peptide p286.
###end p 67
###begin p 68
###xml 75 77 75 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 140 147 140 147 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 140 147 140 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007034-t001"><bold>Table 1</bold></xref>
###xml 182 184 182 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 339 341 339 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 486 493 486 493 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 486 493 486 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007034-t002"><bold>Table 2</bold></xref>
Interaction energies of p286, p509, p524, p530 and p570 in complex with I-Ag7 were calculated based on 3-D modeling structures. As shown in Table 1, the energy of p524 binding to I-Ag7 was markedly lower than that of p509 and p530, but comparable to that of p286 and p570. To understand the mode of interaction between the peptides and I-Ag7 more fully, the domains in the peptide sequence were identified by computer graphics technology and distance geometry methods and were shown in Table 2.
###end p 68
###begin title 69
###xml 70 72 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
The interaction energy (KJ/mol) between the indicated peptides and I-Ag7.
###end title 69
###begin p 70
###xml 135 137 135 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
Interaction energies were calculated under CVFF based on the 3-D theoretical structure of the peptides in complex with MHC class II I-Ag7. The theoretical interaction energy was composed of Van der Waals interactions and electrostatic potential.
###end p 70
###begin title 71
###xml 28 30 28 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
The identified domain in I-Ag7 by the indicated peptides.
###end title 71
###begin p 72
###xml 176 178 176 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
Interaction domains were determined using computer graphic technology and distance geometry methods based on the 3-D structures of the peptides in complex with MHC class II I-Ag7.
###end p 72
###begin p 73
Overall, considering differences in structures of the peptide-MHC class II complexes, interaction energies and identified domains, we concluded that peptides p524 and p570 possessed similar structures to p286, while peptides p509 and p530 were significantly different from the above peptides. Thus, we hypothesized that p570 might be a protective epitope.
###end p 73
###begin p 74
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
P570 stimulation expands CD4+CD25+Foxp3+ T cells from NOD mice
###end p 74
###begin p 75
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 87 94 87 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Results</xref>
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 200 201 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 206 207 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 241 257 241 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9a and 9b</bold>
###xml 241 257 241 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g009"><bold>Figure 9a and 9b</bold></xref>
###xml 371 380 371 380 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9c</bold>
###xml 371 380 371 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g009"><bold>Figure 9c</bold></xref>
###xml 429 430 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 434 435 434 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 511 520 511 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9d</bold>
###xml 511 520 511 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g009"><bold>Figure 9d</bold></xref>
###xml 526 527 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 531 532 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 668 677 665 674 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9e</bold>
###xml 668 677 665 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g009"><bold>Figure 9e</bold></xref>
To test this hypothesis, the ability of p570 to expand CD4+CD25+ T cells was examined. Results showed that the stimulation of p570 led to a significant increase in the frequency and number of CD4+CD25+Foxp3+ T cells after 7-10 days culture (Figure 9a and 9b). Treg-associated phenotype expression, including CTLA-4, GITR, ICOS, and LAG-3, was also markedly up-regulated (Figure 9c). The suppressive capacity of these expanded CD4+CD25+ T cells was determined by active inhibition of the proliferation of Teffs (Figure 9d). CD4+CD25+ T cells expanded by p570 stimulation produced high levels of IL-2, IL-10 and TGF-beta comparable to those induced by p524 stimulation (Figure 9e). Taken together, these data indicate that p570 was a potential epitope for Treg expansion.
###end p 75
###begin title 76
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
In vitro expansion of CD4+CD25+ T cells by p570 stimulation.
###end title 76
###begin p 77
###xml 216 217 216 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 222 223 222 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 234 235 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 279 280 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 290 291 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 526 527 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 531 532 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 609 610 609 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 776 777 773 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 781 782 778 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 852 853 847 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Splenic lymphocytes were isolated from one NOD mice (total number of mice is 8) and cultured with synthesized p570 (50 ng/ml) for 7-10 d. Cells were collected and assayed by flow cytometry. (a) The percentage of CD25+Foxp3+ within CD4+cells was presented. (b) Total number of CD4+CD25+Foxp3+ T cells in each group after expansion. Data collected from three independent experiments are shown. (c) Expression of the Treg-related phenotype (CTLA-4, GITR, ICOS, LAG-3) in CD4 T cells in each group. (d) Fresh and p570-expanded CD4+CD25+ T cells (R) were compared for their ability to suppress proliferation of CD4+ effector T cells (E) under the same conditions as other peptides indicated above. (e) After incubation with p570, IL-2, IL-10 and TGF-beta production of expanded CD4+CD25+ T cells was assayed by sandwich ELISA. Data shown are means+/-SD. *, P<0.05 compared with controls.
###end p 77
###begin p 78
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
P570-expanded CD4+CD25+ T cells suppress diabetes development in cotransfer models
###end p 78
###begin p 79
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 179 180 179 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 184 185 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 249 259 249 259 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 10a</bold>
###xml 249 259 249 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g010"><bold>Figure 10a</bold></xref>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 312 313 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 386 396 386 396 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 10b</bold>
###xml 386 396 386 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g010"><bold>Figure 10b</bold></xref>
###xml 447 448 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 452 453 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 717 718 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 722 723 716 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 733 749 727 743 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 10a and b</bold>
###xml 733 749 727 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g010"><bold>Figure 10a and b</bold></xref>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
We also investigated the suppressive function of p570-expanded CD4+CD25+ T cells in two transfer models as described above. Like p524-expanded CD4+CD25+ T cells, p570-expanded CD4+CD25+ T cells actively inhibited diabetes transfer to NOD.scid mice (Figure 10a), and the transfer of 1x106 p570-stimulated CD4+CD25+ T cells was sufficient to prevent overt autoimmunity in young NOD mice (Figure 10b). Again, our data indicated that p570-expanded CD4+CD25+ T cell-mediated protective effects in two models were partially due to IL-10/TGF-beta secretion of these cells as blockade of IL-10/TGF-beta activities in vivo dramatically abrogated the prevention from diabetes development which was mediated by p570-expanded CD4+CD25+ T cells (Figure 10a and b). Overall, these data suggest that p570 is also a protective peptide epitope.
###end p 79
###begin title 80
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
P570-expanded CD4+CD25+ T cells suppressed development of diabetes.
###end title 80
###begin p 81
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 211 212 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 270 271 270 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 289 290 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 404 425 401 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 553 554 550 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 572 573 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 577 578 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 699 700 696 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 718 719 715 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 723 724 720 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 768 769 765 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 773 774 770 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 939 940 936 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 958 959 955 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 963 964 960 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1073 1094 1067 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 1218 1219 1212 1213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1237 1238 1231 1232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1242 1243 1236 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1330 1331 1324 1325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1349 1350 1343 1344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1354 1355 1348 1349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
###xml 1193 1197 <span type="species:ncbi:10090">mice</span>
###xml 1392 1396 <span type="species:ncbi:10090">mice</span>
(a) Diabetic splenocytes (1x107) were co-transferred with CD4+CD25+ T cells expanded by p570 to 4-8 wk old NOD.scid mice at the numbers indicated. Control recipients were injected with diabetic splenocytes (1x107) alone. In some cases, NOD.scid recipients receiving 6x106 p570-expanded CD4+CD25+ T cells were injected with neutralizing antibodies to IL-10/TGF-beta according to the regimens described in Materials and Methods. Blood glucose levels were monitored for up to 8 wks. Differences between diabetic spleens alone and diabetic spleens plus 3x106 p570-expanded CD4+CD25+ T cells were significant (P = 0.0039), as were differences between diabetic spleens alone and diabetic spleens plus 6x106 p570-expanded CD4+CD25+ T cells (P = 0.0031). (b) P570-expanded CD4+CD25+ T cells were transfused into 4-6 wk old NOD mice at the numbers indicated. Untreated littermates were used as controls. In some cases, NOD recipients receiving 3x106 p524-expanded CD4+CD25+ T cells were injected with neutralizing antibodies to IL-10/TGF-beta according to the regimens described in Materials and Methods. Development of diabetes was monitored over 25 wks. The difference between untreated controls and mice transfused with 1x106 p570-expanded CD4+CD25+ T cells was significant (P = 0.0043), as was the difference between untreated and 3x106 p570-expanded CD4+CD25+ T cells (P = 0.0025). The number of mice in each group is indicated in parentheses.
###end p 81
###begin title 82
Discussion
###end title 82
###begin p 83
###xml 138 142 138 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tarbell2">[39]</xref>
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Fisson1">[42]</xref>
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-OchoaRepraz1">[43]</xref>
###xml 573 580 573 580 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
###xml 662 663 662 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 667 668 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 673 674 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 683 691 683 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 696 697 696 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 701 702 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 830 838 830 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 899 906 899 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 928 929 928 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 933 934 933 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cell therapy for treating progressive autoimmune diseases based on in vitro expansion of Tregs has been established in the past few years [39], [42]-[43]. However, the efficiency of this strategy requires further improvement. Key issues needing to be resolved is whether the acquisition of therapeutic Tregs depends on the peptide epitope used and dissecting the relationship between the physical-chemical properties of epitopes and their function in inducing/expanding therapeutic Tregs. In the current study, we first addressed the capacity of three epitopes from the GAD500-585 region which were significantly different in structural properties, to expand CD4+CD25+Foxp3+ T cells in vitro. CD4+CD25+ T cells, expanded in response to stimulation with either epitopes p509, p530 or p524, exhibited excellent suppressive capacity in vitro. Intriguingly, when their suppression capability was tested in vivo, only p524-pulsed CD4+CD25+ T cells exhibited suppressive effects on diabetes development in co-transfer models.
###end p 83
###begin p 84
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 124 125 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 129 130 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 301 309 301 309 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 301 309 301 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g004"><bold>Figure 4</bold></xref>
###xml 475 476 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 508 509 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 513 514 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 630 637 627 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 749 750 743 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 754 755 748 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 765 774 759 768 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4b</bold>
###xml 765 774 759 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g004"><bold>Figure 4b</bold></xref>
###xml 774 779 768 773 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and </bold>
###xml 779 781 773 775 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5b</bold>
###xml 779 781 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g005"><bold>5b</bold></xref>
###xml 949 953 943 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Bommireddy1">[44]</xref>
###xml 955 959 949 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Roncarolo1">[45]</xref>
###xml 1014 1015 1008 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1019 1020 1013 1014 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1136 1140 1130 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tang1">[32]</xref>
###xml 1155 1162 1149 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1407 1414 1401 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1465 1466 1459 1460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1470 1471 1464 1465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1254 1258 <span type="species:ncbi:10090">mice</span>
###xml 1505 1509 <span type="species:ncbi:10090">mice</span>
This discrepancy between in vivo and ex vivo data appears not to result from the transfer of fewer p509 or p530-expanded CD4+CD25+ T cells compared to those expanded by p524, as even a 3-5 fold increase (e.g. 3-5x106) in p509 or p530-expanded CD4+CD25+ T cells failed to inhibit transfer of diabetes (Figure 4). The data presented in this study indicate that this failure to inhibit transfer of diabetes may be attributed to the differential cytokine profiles of expanded CD4+CD25+ T cells. P524-expanded CD4+CD25+ T cells produced higher levels of IL-10 and TGF-beta than those expanded by p509 or p530 stimulation. Furthermore, in vivo neutralization of IL-10/TGF-beta bioactivities led to the abrogation of protective effects of p524-expanded CD4+CD25+ T cells (Figure 4b and 5b), which is consistent with the well-accepted conception that these two categories of cytokines are recognized as important mediators of Treg immunomodulatory function [44], [45]. In addition, differences between epitope-expanded CD4+CD25+ T cells in terms of migration to or re-activation in the draining lymph nodes also need consideration. Tang et al. [32] proposed that ex vivo-expanded BDC2.5-specific Tregs underwent significant proliferation after transfer into NOD mice. However, expanded GAD286-specific Tregs failed to proliferate in pancreatic lymph nodes. Whether this difference in proliferation and/or migration in vivo is also present in p524, p509 or p530-expanded CD4+CD25+ T cells when transfused into NOD mice needs to be elucidated in further studies.
###end p 84
###begin p 85
As well known, to deeply understand the biological role of the protein or peptides, the 3-D structure of them will be required. Although experimental structure determination methods are providing high-resolution structure information about a subset of the proteins, computational structure predictions will provide valuable information for the large fraction of sequences whose structures will not be determined experimentally.
###end p 85
###begin p 86
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Deng1">[46]</xref>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Nicholson1">[47]</xref>
###xml 310 313 310 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Quinn1">[9]</xref>
###xml 426 428 426 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 619 620 619 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 845 853 845 853 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6</bold>
###xml 845 853 845 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g006"><bold>Figure 6</bold></xref>
###xml 853 858 853 858 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and </bold>
###xml 858 859 858 859 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 858 859 858 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g007"><bold>7</bold></xref>
###xml 929 931 929 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 1017 1021 1017 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Arneson1">[48]</xref>
###xml 662 666 <span type="species:ncbi:10090">mice</span>
###xml 939 943 <span type="species:ncbi:10090">mice</span>
Recently, studies have indicated that the biological functions of the peptide-major histocompatible complex (MHC) depend on the structural property of the peptide [46], [47]. Here, we focused on the correlation of epitope structural properties with their functions in expanding therapeutic Tregs. Quinn et al. [9] carried out experiments on peptide epitope immunization and showed that GAD524-543 consisted of at least two I-Ag7-restricted determinants (p524 and p530, GAD530-543), with apparently distinct properties. P524-specific T cells dominate the protective response after immunization with GAD524-543, while CD4+ T cells arise spontaneously in young NOD mice in response to a dominant determinant found within p530. Consistent with this we have shown a difference in structural properties between p524 and p530 using molecular modeling (Figure 6 and 7). This difference may influences the conformation of MHC class II I-Ag7 in NOD mice when bound to the corresponding peptide epitopes, as previously reported [48].
###end p 86
###begin p 87
###xml 68 70 68 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 185 187 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 187 191 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Corper1">[49]</xref>
###xml 245 247 245 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Tarbell3">[41]</xref>
###xml 547 549 547 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 660 662 660 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 758 766 758 766 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8</bold>
###xml 758 766 758 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007034-g008"><bold>Figure 8</bold></xref>
###xml 866 868 866 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
To address this issue, the patterns of p524, p530, p509 bound to I-Ag7 were determined by molecular modeling using the structural framework of GAD peptide p207 (GAD207-220) bound to I-Ag7[49]. The structural properties and binding pattern to I-Ag7 of another defined protective GAD peptide epitope, p286 (GAD286-300) [41], used here as a positive control, were also analysed. We found that the secondary structures of p524 and p286 were alpha-helices and stable, while peptides p509 and p530 were coiled and very flexible. The 3-D structure of I-Ag7 in complex with peptides p509, p524, p530 and p286 revealed two kinds of binding mode; the binding mode of I-Ag7 to p524 and p286 was similar, but markedly different from its binding mode with p509 and p530 (Figure 8). Overall, our data strongly suggest that protective peptide epitopes p524 and p286, binding to I-Ag7, could form a unique conformation on the surface of APCs, allowing for the induction of Tregs.
###end p 87
###begin p 88
###xml 171 173 171 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 240 242 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
###xml 385 386 382 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 390 391 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
To support this premise we analyzed another epitope p570, which is very similar to p524 in sequence tendency, surface electrostatic potential and interaction mode with I-Ag7. Similar structural properties and binding patterns of p570 to I-Ag7, to those of p524 or p286 were revealed in this analysis. The fact that p570 stimulation facilitated induction of IL-10/TGF-beta-secreting CD4+CD25+ T cells indicates that p570 is a protective epitope. Therefore, while further comprehensive study is required, our present data highlight that computer modeling-based T cell-epitope study is a promising tool for function prediction of many autoimmune-related epitopes. We are currently analyzing the epitopes of another two critical autoimmune diabetes-related autoantigens (i.e. insulin and IA-2) using molecular modeling.
###end p 88
###begin p 89
###xml 594 598 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Zekzer1">[50]</xref>
###xml 600 604 600 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007034-Severe1">[51]</xref>
###xml 962 969 962 969 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
To our knowledge, this is the first report of molecular modeling-based analysis of T cell epitope function and prediction. Classical approaches, such as use of 15-mer overlapping synthetic peptides, are costly and time-consuming. With the help of molecular modeling, it will become possible to carry out large-scale screening of antigen/peptide targets, providing valuable structural information as well as predicting potential epitopes and their functions. Interestingly, to date, several of the GAD-specific clones isolated have been found to be pathogenic and quite a few are non-pathogenic [50], [51]. Accumulating evidence indicates that many GAD-specific responses may be protective and not diabetogenic. As a result, it is reasonable that GAD should be used preferentially as an immunogen to induce protective effects or to abrogate aggressive autoimmunity. The present study proposes two important regulatory epitopes (p524 and p570) in the region of GAD500-585 for expanding functional Tregs. These findings may be helpful for the design of autoimmune-related autoantigen epitopes for immune intervention and achievement of therapeutic epitope-specific Tregs.
###end p 89
###begin p 90
We thank Ming Yu for excellent technical assistance.
###end p 90
###begin title 91
References
###end title 91
###begin article-title 92
###xml 71 77 <span type="species:ncbi:10090">murine</span>
Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes.
###end article-title 92
###begin article-title 93
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease.
###end article-title 93
###begin article-title 94
The clinical significance of an autoimmune response against glutamic acid decarboxylase.
###end article-title 94
###begin article-title 95
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice.
###end article-title 95
###begin article-title 96
Response of peripheral blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes.
###end article-title 96
###begin article-title 97
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells.
###end article-title 97
###begin article-title 98
Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes.
###end article-title 98
###begin article-title 99
###xml 100 106 <span type="species:ncbi:10090">murine</span>
Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes.
###end article-title 99
###begin article-title 100
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Regulatory and effector CD4 T cells in nonobese diabetic mice recognize overlapping determinants on glutamic acid decarboxylase and use distinct V beta genes.
###end article-title 100
###begin article-title 101
###xml 105 109 <span type="species:ncbi:10090">mice</span>
Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice.
###end article-title 101
###begin article-title 102
Induction of autoantigen-specific Th2 and Tr1 cells and modulation of autoimmune diabetes.
###end article-title 102
###begin article-title 103
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses.
###end article-title 103
###begin article-title 104
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD25+CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes.
###end article-title 104
###begin article-title 105
###xml 180 187 180 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">500&#8211;585</sub>
Active tolerance induction and prevention of autoimmune diabetes by immunogene therapy using recombinant adenoassociated virus expressing glutamic acid decarboxylase 65 peptide GAD500-585.
###end article-title 105
###begin article-title 106
Construction of two mathematical models for prediction of bacterial sRNA targets.
###end article-title 106
###begin article-title 107
Prediction of protein antigenic determinants from amino acid sequences.
###end article-title 107
###begin article-title 108
GOR method for predicting protein secondary structure from amino acid sequence.
###end article-title 108
###begin article-title 109
Prediction of sequential antigenic regions in proteins.
###end article-title 109
###begin article-title 110
Surface and inside volumes in globular proteins.
###end article-title 110
###begin article-title 111
Ab initio modeling and molecular simulation of the alpha 1b-adrenergic receptor activation.
###end article-title 111
###begin article-title 112
Ab initio folding of proteins using restraints derived from evolutionary information.
###end article-title 112
###begin article-title 113
###xml 104 105 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta?
###end article-title 113
###begin article-title 114
Control of regulatory T cell development by the transcription factor Foxp3.
###end article-title 114
###begin article-title 115
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
###end article-title 115
###begin article-title 116
Foxp3 in control of the regulatory T cell lineage.
###end article-title 116
###begin article-title 117
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.
###end article-title 117
###begin article-title 118
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.
###end article-title 118
###begin article-title 119
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion.
###end article-title 119
###begin article-title 120
Role of LAG-3 in regulatory T cells.
###end article-title 120
###begin article-title 121
Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity.
###end article-title 121
###begin article-title 122
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells.
###end article-title 122
###begin article-title 123
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro-expanded autoantigen-specific regulatory T cells suppress autoimmune diabetes.
###end article-title 123
###begin article-title 124
T cell regulation as a side effect of homeostasis and competition.
###end article-title 124
###begin article-title 125
T cell regulation: a special job or everyone's responsibility?
###end article-title 125
###begin article-title 126
###xml 74 75 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 79 80 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Single cell analysis shows decreasing FoxP3 and TGF-beta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes.
###end article-title 126
###begin article-title 127
Multiple immuno-regulatory defects in type-1 diabetes.
###end article-title 127
###begin article-title 128
How defects in central tolerance impinge on a deficiency in regulatory T cells.
###end article-title 128
###begin article-title 129
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice.
###end article-title 129
###begin article-title 130
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
Dendritic cell-expanded, islet-specific CD4+CD25+CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice.
###end article-title 130
###begin article-title 131
###xml 151 155 <span type="species:ncbi:10090">mice</span>
N-terminal flanking residues of a diabetes-associated GAD65 determinant are necessary for activation of antigen-specific T cells in diabetes-resistant mice.
###end article-title 131
###begin article-title 132
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 80 95 <span type="species:ncbi:10090">transgenic mice</span>
CD4+ T cells from glutamic acid decarboxylase (GAD)65-specific T cells receptor transgenic mice are not diabetogenic and can delay diabetes transfer.
###end article-title 132
###begin article-title 133
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Therapeutic potential of self-antigen-specific CD4+CD25+ regulatory T cells selected in vitro from a polyclonal repertoire.
###end article-title 133
###begin article-title 134
Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis.
###end article-title 134
###begin article-title 135
TGF-beta1 and Treg cell: alliance for tolerance.
###end article-title 135
###begin article-title 136
###xml 66 72 <span type="species:ncbi:9606">humans</span>
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.
###end article-title 136
###begin article-title 137
Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor,
###end article-title 137
###begin article-title 138
Unusual features of self-peptide/MHC binding by autoimmune T cell receptors,
###end article-title 138
###begin article-title 139
###xml 29 31 29 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
The MHC class II molecule I-Ag7 exists in alternate conformations that are peptide dependent.
###end article-title 139
###begin article-title 140
###xml 59 61 59 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g7</sup>
A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes.
###end article-title 140
###begin article-title 141
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice.
###end article-title 141
###begin article-title 142
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 103 108 <span type="species:ncbi:10090">mouse</span>
CD8+ T lymphocytes specific for glutamic acid decarboxylase 90-98 epitope mediate diabetes in NOD/SCID mouse.
###end article-title 142
###begin p 143
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 143
###begin p 144
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the National Key Basic Research Program of China (2007CB512406) and the National Natural Science Foundation of China (30801029). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 144

